Clinical Trials Logo

Filter by:
NCT ID: NCT04707261 Recruiting - Heart Failure Clinical Trials

Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)

ADIDAS
Start date: August 6, 2021
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to investigate the hemoglobin change and association between hemoglobin change and readmissions due to heart failure, and all-cause death in patients with heart failure treated with dapagliflozin or placebo.

NCT ID: NCT04707105 Recruiting - Clinical trials for Intracerebral Hemorrhage

Prospective Cohort Study of Intracerebral Hemorrhage

POSTER
Start date: December 29, 2020
Phase:
Study type: Observational

The investigators design a prospective, observational cohort study to provide contemporary information on the prevalence, characteristics, risk stratification,cost-effective ,treatments and prognosis of Chinese hospitalised adult patients with intracerebral hemorrhage.

NCT ID: NCT04707079 Recruiting - Follicular Lymphoma Clinical Trials

A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma

Start date: December 18, 2019
Phase: Phase 2
Study type: Interventional

This is a phase 2 clinical trial to evaluate the safety and efficacy of duvelisib as a monotherapy in subjects diagnosed with follicular lymphoma (FL) that is relapsed or refractory to either chemotherapy or radioimmunotherapy (RIT).

NCT ID: NCT04706949 Recruiting - Clinical trials for Lung Cancer, Non-small Cell

Pyrotinib Combined With Pemetrexed Plus Carboplatin in the First-line Treatment

Start date: December 7, 2020
Phase: Phase 2
Study type: Interventional

A prospective, single center, single arm, phase II clinical trial of Pyrotinib combined with pemetrexed plus carboplatin in the first-line treatment of patients with HER2 mutant or amplified recurrent / metastatic non-small cell lung cancer

NCT ID: NCT04706936 Recruiting - Clinical trials for Relapsed or Refractory Multiple Myeloma

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

Start date: April 1, 2021
Phase: Phase 1
Study type: Interventional

This study evaluates the safety and efficacy of novel BCMA-targeted CAR-T cell therapy (CBG-002) for patients with relapsed or refractory multiple myeloma (r/r MM). CBG-002 is designed based on the fourth-generation of CAR-T techonology.

NCT ID: NCT04706611 Recruiting - Clinical trials for Fecal Microbiota Transplantation

Efficacy and Safety of Fecal Microbiota Transplantation

FMT
Start date: January 15, 2021
Phase: N/A
Study type: Interventional

In recent years, researches illustrate that multifactorial diseases such as functional gastrointestinal disorders, autoimmune diseases, metabolic, behavioral and neurological diseases are associated with an abnormal microbiome structure-dysbiosis, which means the imbalance of the microbiome community. Fecal microbiota transplantation (FMT), the infusion of faeces from a healthy donor to the gastrointestinal tract of a recipient patient aiming to alter the intestine microbiota, is recommended to be performed in Clostridium difficile infection(CDI) as the most effective therapy. It also being used experimentally in the treatment of the disease states linked to dysbiosis of the intestinal microbiota. However, the efficacy and safety of FMT to treat the dysbiosis-associated diseases is still in its infancy. To further verify the indications above, more data is required to be collected through studies.

NCT ID: NCT04706598 Recruiting - Immunotherapy Clinical Trials

Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment

Start date: June 9, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of bladder intravesical Camrelizumab in patients with high-risk non-muscle-invasive bladder cancer who failed BCG therapy.

NCT ID: NCT04706455 Recruiting - Dry Eye Clinical Trials

Effect of Artificial Tears on the Parameters of the Eye and Its Impact on IOL Power Calculation for Cataract Surgery

IOL
Start date: December 1, 2020
Phase: N/A
Study type: Interventional

First, preoperative biometry of the eye at the IOL Master® will be performed. Then, corneal topography will be measured at the Oculus pentacam®. Afterwards, one of two eye drops are instilled in the eye, and biometry and corneal topography will be repeated after 5 minutes. For all patients, the Barrett Universal II formula will be used for calculation of IOL power. Predicted refraction outcome will be referred to as SEQ. The chief surgeon will perform the uneventful standard cataract operation with in-the-bag implantation of a HOYA IOL (Model 251) through a 2.4-mm corneal incision. A Subjective Refraction using plus principle will be performed one month after the operation, and ETDRS visual acuity charts will be used to measure best-corrected visual acuity. Refraction will be described as SR (postoperative SEQ) and will be calculated as: SR = sphere + (0.5*cylinder)

NCT ID: NCT04706338 Recruiting - Glioma Clinical Trials

Transcranial Magnetic Stimulation in the Rehabilitation of Postoperative Motor Dysfunction.

ATM
Start date: January 15, 2021
Phase: N/A
Study type: Interventional

This study focused on glioma patients with postoperative motor deficits, especially for patients with supplementary motor area syndrome. The investigators want to investigate whether the recovery of motor function will be accelerated by using transcranial magnetic stimulation to stimulate primary motor area and supplementary motor area on the lesional hemisphere.

NCT ID: NCT04705974 Recruiting - Hip Fractures Clinical Trials

MED90 of Ropivacaine for Peripheral Nerve Block on Posture-evoked Pain in Spinal Anesthesia Positioning

Start date: January 25, 2022
Phase: N/A
Study type: Interventional

This study aims to determine the minimum effective dose of ropivacaine for peripheral nerve block on posture-evoked pain for spinal anesthesia in elderly patients with hip fracture. Three types of peripheral nerve block, including fascia iliaca block, femoral nerve block and Pericapsular nerve group block (PENG block) will be assessed.